Drugs / Terelizumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05833672 | May 2023 → Dec 2025 | colon carcinoma | fan li | Unknown | No outcome recorded |
| Phase 2 | NCT05515796 | Sep 2022 → Mar 2026 | chemotherapy-induced toxicity, gastric cancer, rectal cancer | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Terelizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05833672 ↗ |
| Known as | Tislelizumab | “q3w Terelizumab (aka Tislelizumab) 200mg on day 1 of each cycle” NCT05515796 ↗ |